(Q425729)

17 November 2015

Ivabradine 2.svg
512 × 176; 4 KB

0 references

mass

468.262422 dalton

1 reference

Ivabradine (English)

20 September 2016

1 reference

C₂₇H₃₆N₂O₅

1 reference

Ivabradine (English)

19 November 2016

CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC

1 reference

Ivabradine (English)

19 November 2016

CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC

1 reference

https://www.whocc.no/atc_ddd_index/?code=C01EB17

Ivabradine (English)

19 November 2016

10 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

Ivabradine (English)

1 reference

title

Ivabradine (English)

medical condition treated

19 January 2016

congestive heart failure

1 reference

Drug Indications Extracted from FAERS

2 October 2018

cardiomyopathy

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

verapamil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fingolimod

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pasireotide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

donepezil

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

galantamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

toremifene

1 reference

A reference set of clinically relevant adverse drug-drug interactions

voriconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moxifloxacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vandetanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pasireotide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

toremifene

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moxifloxacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fingolimod

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vandetanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pasireotide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

galantamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

donepezil

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

donepezil

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

itraconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

posaconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

voriconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fosphenytoin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Hyperpolarization activated cyclic nucleotide gated potassium channel 1

1 reference

Hyperpolarization activated cyclic nucleotide gated potassium channel 1

17 August 2016

1 reference

Hyperpolarization-activated, cyclic nucleotide-gated K+ 2

17 August 2016

1 reference

Hyperpolarization activated cyclic nucleotide gated potassium channel 3

17 August 2016

1 reference

Hyperpolarization activated cyclic nucleotide gated potassium channel 4

17 August 2016

1 reference

Australian pregnancy category D

17 August 2016

route of administration

oral administration

0 references

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category E

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Ivabradine

last update

20 April 2017

official website

https://www.corlanorhcp.com

1 reference

imported from Wikimedia project

1 reference

Medical Subject Headings

15 March 2018

Ivabradine

0 references

Identifiers

InChI

InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1

1 reference

ACRHBAYQBXXRTO-OAQYLSRUSA-N

Ivabradine (English)

19 November 2016

2 references

Ivabradine (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

155974-00-8

2 references

ACRHBAYQBXXRTO-OAQYLSRUSA-N

ivabradine (English)

19 November 2016

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=155974-00-8

1 reference

Ivabradine (English)

19 November 2016

1 reference

Ivabradine (English)

19 November 2016

mapping relation type

1 reference

IVABRADINE (English)

19 November 2016

1 reference

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

IVABRADINE (English)

19 November 2016

1 reference

inferred from InChIKey

1 reference

1 reference

DSSTOX compound identifier

0 references

0 references

1 reference

title

Ivabradine (English)

publication date

17 November 2015

1 reference

ivabradine (English)

19 November 2016

Ivabradine

0 references

0 references

1 reference

ivabradine (English)

19 November 2016

1 reference

Ivabradine (English)

19 November 2016

1 reference

title

ivabradine (English)

MedlinePlus drug identifier

19 November 2016

0 references

1 reference

ivabradine (English)

19 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

Ivabradine (English)

19 January 2016

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

UMLS CUI

C0257190

1 reference